Caspofungin in the treatment of oropharyngeal candidiasis

International Journal of Clinical Practice

Volumn 57, Issue 2, 2003, Pages 143-144

  Garbino, Jorge ^a   Lew, D ^a   Hirschel, B ^a   Rohner, P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE PANCREATITIS; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; CHRONIC DIARRHEA; DRUG RESPONSE; FUNGUS ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALE; OROPHARYNX; PANCYTOPENIA; POLYNEUROPATHY; PRIORITY JOURNAL; SEPSIS; THRUSH; TREATMENT FAILURE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC; PHARYNGEAL DISEASES; TREATMENT OUTCOME;

EID: 0037346306     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: S5-S-14.
2. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 20: 662-678.
3. Masia CM, Guiterrez RF, Ortiz de la Tabla DV et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis 2000; 19: 593-601.
4. Ruhnke M, Eigler A, Tennagen I et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092-2098.
5. Newman SL, Flanigan TP, Fisher A et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994; 19: 684-686.
6. Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 27: 1291-565.
7. Martinez-Suarez JV, Rodriguez-Tudela JL. In vitro activities of semi-synthetic pneumocandin L-733,560 against fluconazole-resistant and fluconazole-susceptible Candida albicans isolates. Antimicrob Agents Chemother 1996; 40: 1277-1279.
8. Andriole VT. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999; 44: 151-162.
9. Vazquez JA, Lynch M, Boikov D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and azole-resistant Candida species. Antimicrob Agents Chemother 1997; 41: 1612-1614.
10. Bachman SP, Pera S, Kirkpatrick WR et al. In vitro activity of Cancidas™ (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000; 352.
11. Kartsonis N, Bartizal K, Hicks PS et al. Caspofungin for fluconazole-resistant esophageal candidiasis. Presented at the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October, 2001.
12. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2002; 33: 1529-1535.